Trials / Completed
CompletedNCT03697161
A Study of OV101 in Individuals With Fragile X Syndrome
A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Healx AI · Industry
- Sex
- Male
- Age
- 13 Years – 22 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101 (gaboxadol) in subjects with Fragile X syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OV101 (gaboxadol) | OV101 (gaboxadol) |
Timeline
- Start date
- 2018-09-17
- Primary completion
- 2020-02-03
- Completion
- 2020-02-26
- First posted
- 2018-10-05
- Last updated
- 2024-01-23
- Results posted
- 2024-01-23
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03697161. Inclusion in this directory is not an endorsement.